<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549301</url>
  </required_header>
  <id_info>
    <org_study_id>FILBLA1211I</org_study_id>
    <secondary_id>Version 01 - 09/12/2011</secondary_id>
    <nct_id>NCT01549301</nct_id>
  </id_info>
  <brief_title>Evaluation of Pharmacokinetic and Pharmacodynamic Parameters of Filgrastim (G-CSF)Produced by Blausiegel Indústria e Comércio Ltda. Compared to Granulokine Produced by Produtos Roche Químicos e Farmacêuticos S/A.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azidus Brasil</source>
  <brief_summary>
    <textblock>
      The primary aim of this study is to compare the pharmacokinetic and pharmacodynamic effects
      of two commercial preparations of filgrastim (T and C), after single dose via subcutaneous or
      intravenous administration at a concentration of 5 mcg/kg or 10 mcg/kg in healthy subjects
      through the alteration in the pharmacokinetic and pharmacodynamic parameters (measurement of
      serum levels of G-CSF and absolute neutrophil count - ANC).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy parameters will be based on the investigation of pharmacokinetics and pharmacodynamics of filgrastim in research subjects after administration of single dose via sc or iv routes at doses of 5 or 10 mcg/kg of the drug.</measure>
    <time_frame>• PK.: 0, 15 min., 30 min., 45 min., 1h, 1h e 30min., 2h, 3h, 4h, 6h, 8h,10h, 12h, 16h, 24h and 48h. • PD (ANC): 0, 30 min., 1h, 2h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 32h, 48h, 72h, 96h and 120h</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Group D 10 i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two periods, crossover, single dose, i.v., 10 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C 5 i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two periods, crossover, single dose, i.v., 5 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B 10 s.c.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two periods, crossover, single dose, s.c., 10 mcg/kg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A 5 s.c.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two periods, crossover, single dose, s.c., 5 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>filgrastim, single dose, s.c., dosage: 5 mcg/kg</description>
    <arm_group_label>Group A 5 s.c.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>filgrastim, single dose, s.c., dosage: 10 mcg/kg</description>
    <arm_group_label>Group B 10 s.c.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Filgrastim, i.v., single dose, dosage: 5 mcg/kg</description>
    <arm_group_label>Group C 5 i.v.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Filgrastim, i.v., single dose, dosage: 10 mcg/kg</description>
    <arm_group_label>Group D 10 i.v.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Agree with all study procedures, sign and date back by their own free will, the IC;

          -  Be between 18 and 50 years, of both sexes;

          -  Present a body mass index (BMI) greater than or equal to 20 and less than or equal to
             28;

          -  are considered healthy, clinical, psychological and laboratory;

          -  are female, but they have and maintain a safe method of contraception during the
             study.

        Exclusion Criteria:

          -  Known hypersensitivity to filgrastim;

          -  Hypersensitivity to products derived from E. coli;

          -  fever or infectious disease in the 07 days preceding the first administration;

          -  Positive serology for hepatitis B or C and HIV;

          -  Prior treatment with CSFs, interleukins and interferons;

          -  Participation in a clinical study in the last 12 months;

          -  Donation or loss of blood in the 03 months preceding the study;

          -  General anesthesia in the 03 months preceding the study;

          -  Provide a history of alcohol abuse, drug or drugs;

          -  Have a history of liver disease, renal, pulmonary, gastrointestinal, hematological,
             psoriasis, gout, acute myocardial infarction, thyroid or psychiatric disease;

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexandre Frederico, Dr</last_name>
    <phone>(55) 19 38716399</phone>
    <email>alexandre@lalclinica.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>LAL Clinica Pesquisa e Desenvolvimento Ltda</name>
      <address>
        <city>Valinhos</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <last_update_submitted>March 6, 2012</last_update_submitted>
  <last_update_submitted_qc>March 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

